Apellis Pharmaceuticals (APLS) Profit After Tax (2020 - 2025)
Historic Profit After Tax for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $215.7 million.
- Apellis Pharmaceuticals' Profit After Tax rose 47551.57% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 11798.71%. This contributed to the annual value of -$197.9 million for FY2024, which is 6256.76% up from last year.
- According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Profit After Tax is $215.7 million, which was up 47551.57% from -$42.2 million recorded in Q2 2025.
- In the past 5 years, Apellis Pharmaceuticals' Profit After Tax registered a high of $215.7 million during Q3 2025, and its lowest value of -$219.2 million during Q2 2021.
- Its 5-year average for Profit After Tax is -$107.6 million, with a median of -$138.9 million in 2022.
- As far as peak fluctuations go, Apellis Pharmaceuticals' Profit After Tax tumbled by 28901.55% in 2021, and later skyrocketed by 47551.57% in 2025.
- Apellis Pharmaceuticals' Profit After Tax (Quarter) stood at -$147.9 million in 2021, then dropped by 12.21% to -$166.0 million in 2022, then skyrocketed by 46.64% to -$88.6 million in 2023, then soared by 58.96% to -$36.4 million in 2024, then soared by 693.39% to $215.7 million in 2025.
- Its Profit After Tax was $215.7 million in Q3 2025, compared to -$42.2 million in Q2 2025 and -$92.2 million in Q1 2025.